Search results

717 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

Proposed [GID-TA10781] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]

Proposed [GID-TA10746] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Proposed [GID-TA10811] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

Proposed [GID-TA10812] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]

Proposed [GID-TA10813] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]

Proposed [GID-TA10814] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]

Proposed [GID-TA10815] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]

Proposed [GID-TA10816] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]

Proposed [GID-TA10817] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating active ankylosing spondylitis [ID3865]

Proposed [GID-TA10771] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Proposed [GID-TA10706] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]

Proposed [GID-TA10719] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: TBC

Type

NICE guideline

Status

In development
Pernicious anaemia

In development [GID-NG10176] Expected publication date: 23 March 2023

Type

NICE guideline

Status

In development
Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 20 July 2022

Type

NICE guideline

Status

In development
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

Type

NICE guideline

Status

In development
Cardiovascular disease: risk assessment and reduction, including lipid modification

In development [GID-NG10178] Expected publication date: 19 April 2023

Type

NICE guideline

Status

In development
Type 1 diabetes in adults: diagnosis and management (update)

In development [GID-NG10159] Expected publication date: TBC

Type

NICE guideline

Status

In development
Postnatal care

In development [GID-NG10070] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development
Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diabetes update

In development [GID-NG10152] Expected publication date: TBC

Type

NICE guideline

Status

In development
Shared decision making

In development [GID-NG10120] Expected publication date: 17 June 2021

Type

NICE guideline

Status

In development
Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 09 December 2021

Type

NICE guideline

Status

In development
Head injury: assessment and early management

In development [GID-NG10164] Expected publication date: 11 May 2022

Type

NICE guideline

Status

In development
Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development
Epilepsies in children, young people and adults

In development [GID-NG10112] Expected publication date: 09 March 2022

Type

NICE guideline

Status

In development
Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 09 June 2021

Type

NICE guideline

Status

In development
Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 06 July 2022

Type

NICE guideline

Status

In development
Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2023

Type

NICE guideline

Status

In development
Stroke rehabilitation in adults

In development [GID-NG10175] Expected publication date: 14 December 2022

Type

NICE guideline

Status

In development
Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 20 July 2021

Type

NICE guideline

Status

In development
Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10186] Expected publication date: TBC

Type

NICE guideline

Status

In development